インデックス付き
  • 学術雑誌データベース
  • Jゲートを開く
  • Genamics JournalSeek
  • ジャーナル目次
  • 研究聖書
  • ウルリッヒの定期刊行物ディレクトリ
  • 電子ジャーナルライブラリ
  • レフシーク
  • ハムダード大学
  • エブスコ アリゾナ州
  • OCLC-WorldCat
  • 学者の舵取り
  • SWBオンラインカタログ
  • 仮想生物学図書館 (vifabio)
  • パブロン
  • ミアル
  • ジュネーブ医学教育研究財団
  • ユーロパブ
  • Google スカラー
このページをシェアする
ジャーナルチラシ
Flyer image

概要

The Methylation Profile of IFN-γ, SOCS1 and SOCS3 Promoter Regions in End-Stage Renal Disease

Maivel Ghattas, Fatma El-shaarawy, Noha Mesbah and Dina Abo-Elmatty

End-stage renal disease (ESRD) is a state of chronic inflammation. DNA methylation is a major epigenetic modification that has the potential to silence gene expression. IFN-γ and suppressor of cytokine signaling (SOCS) are essential modulators of inflammation. The current study aimed to determine the methylation status of IFN-γ, SOCS1 and SOCS3 promoter regions in DNA isolated from peripheral blood of ESRD patients and controls, in order to correlate this methylation status with the clinical features of ESRD. Ninety six ESRD patients and 96 healthy ethnically, age and gender matched controls were included in the study. The promoter methylation of the studied genes was assessed using the methylation-specific polymerase chain reaction (MSP). Most of our samples were positive for IFN-γ promoter methylation. Full unmethylation was observed only in the ESRD group (7.3%), and statistical difference was observed among groups (P=0.02). IFN-γ unmethylation was associated to a decrease in estimated glomerular filtration rate (eGFR) and an increase in both serum creatinine and total cholesterol levels. For SOCS1 promoter methylation, partial and full methylation were observed only in ESRD patients (5.2% and 2.1%, respectively); however no methylation was detected in controls (P=0.014). SOCS3 promoter methylation was not detected in either the patient or control group. In conclusion, the methylation profile of IFN-γ and SOCS1 promoter regions play an important role in the pathogenesis of ESRD. The present study highlights the role of epigenetics in disease progression.

免責事項: この要約は人工知能ツールを使用して翻訳されており、まだレビューまたは確認されていません